Obama's Precision Medicine Initiative seeks submissions to further vision

In a follow-up to the February announcement of the Obama Administration’s Precision Medicine Initiative (PMI), the White House posted a blog post seeking contributions that further the initiative’s goals.

“We need your creativity, on-the-ground experience and enthusiasm to realize the promise of delivering individually tailored treatments to patients,” wrote DJ Patil, PhD, White House Office of Science and Technology Policy’s deputy CTO for data policy and chief data scientist.

The PMI vision will lead to “a new era of medicine through research, technology and policies that will lead to the development of individualized, tailored treatments for patients… and allow everyone to become an active participant in scientific discovery--furthering an open and inclusive model for better recruitment of and partnership with research participants.”

However, “moving precision medicine forward must be a team effort. We need all sectors to work together. We need people to actively engage in research and voluntarily choose to share their data with responsible researchers who are working to understand health and disease. We need healthcare providers to share their insight and help translate new findings into better care. And we need a strong, secure, and nimble infrastructure for health data that protects privacy, ensures security and facilitates new research models.”

Patil listed key areas, including patient engagement, robust APIs in EHRs, novel analytics, new security solutions and workable models of information sharing.

Submissions will be accepted until Sept. 21. Read the entire blog post.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.